NASDAQ:NXTM - NxStage Medical Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$30.00
+0.30 (1.20%)
Get New NxStage Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NXTM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NXTM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NxStage Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $30.00.

This chart shows the closing price for NXTM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in NxStage Medical. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017Northland SecuritiesReiterated RatingHold$30.00N/A
8/22/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$28.00 ➝ $30.00High
8/11/2017BTIG ResearchDowngradeBuy ➝ NeutralLow
8/9/2017StephensDowngradeOverweight ➝ Equal Weight$33.00 ➝ $30.00Low
8/8/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$33.00 ➝ $30.00Medium
8/7/2017William BlairDowngradeOutperform ➝ Market PerformMedium
8/7/2017Northland SecuritiesReiterated RatingHold$30.00Low
8/7/2017Craig HallumDowngradeBuy ➝ HoldHigh
6/27/2017Craig HallumInitiated CoverageBuy$32.00High
5/10/2017Jefferies Financial GroupLower Price TargetBuy$38.00 ➝ $33.00Medium
5/10/2017BTIG ResearchReiterated RatingBuy$27.00Low
5/4/2017Northland SecuritiesDowngradeOutperform ➝ Market PerformMedium
4/3/2017Northland SecuritiesReiterated RatingBuy$35.00Medium
3/22/2017Jefferies Financial GroupReiterated RatingBuy$38.00Low
2/6/2017Jefferies Financial GroupBoost Price TargetBuy$38.00N/A
(Data available from 1/18/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NxStage Medical logo
NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.
Read More

Today's Range

Now: $30.00
Low: $29.98
High: $30.00

50 Day Range

MA: $30.00
Low: $30.00
High: $30.00

52 Week Range

Now: $30.00
Low: $23.17
High: $30.00

Volume

2,608,346 shs

Average Volume

1,506,712 shs

Market Capitalization

$2.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of NxStage Medical?

The following Wall Street sell-side analysts have issued reports on NxStage Medical in the last year:
View the latest analyst ratings for NXTM.

What is the current price target for NxStage Medical?

0 Wall Street analysts have set twelve-month price targets for NxStage Medical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NxStage Medical in the next year.
View the latest price targets for NXTM.

What is the current consensus analyst rating for NxStage Medical?

NxStage Medical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NXTM.

What other companies compete with NxStage Medical?

How do I contact NxStage Medical's investor relations team?

NxStage Medical's physical mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company's listed phone number is 978-687-4700 and its investor relations email address is [email protected] The official website for NxStage Medical is www.nxstage.com.